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The present study was designed to investigate the hypoglycemic effects of the daily oral dose of 0.50 to 
0.75 g/kg of yeast hydrolysate (YH) containing high Cyclo-His-Pro (51.0 mg CHP/g YH) on normal and 
streptozotocin (STZ)-induced diabetic rats for 14 days. In STZ-induced diabetic rats, after 
administrations of the YH for 14 days, the body weight gain was significantly increased in dose 
dependent manner, and the plasma glucose levels were decreased approximately (60%) as compared to 
the STZ induced diabetic control group. Glucose level showed significant differences between the 
diabetic control (DC) and the YH administered groups in oral glucose tolerance test (OGTT) (P<0.05). 
Results of the OGTT showed a significant decrease in the area under curve (AUC) value of YH 
supplemented groups as compared to the DC group. The present data suggests that the CHP-enriched 
YH has potential anti-diabetic effect, which can help in the cure and management of diabetes. 
 





Diabetes mellitus (DM) is one of the major endocrine 
disorder and global public health problems, affecting 
nearly 10% of the world’s population. DM consists of a 
group of syndromes characterized by hyperglycemia; 
altered metabolism of lipids, carbohydrates and proteins; 
and the increased risk of complications from vascular 
disease (Davis and Granner, 2001). Conventional drugs 
used in its treatment are associated with drawbacks such 
as rigid and multiple dosing regimen, high-cost, inacces-
sibility and untoward effects. Scientific investigations of 
alternatives for diabetes have provided valuable clues for 
the development of therapeutic strategies. In the last few 
decades, there has been exponential growth in the field 
of alternatives by natural supplements, owing to their 
natural origin and lesser side effects (Yeh et al., 2003),  
since natural sources are usually considered to be less 
toxic with fewer side effects than synthetic sources (Pari 
and Umamaheswari, 2000). They have the potential to 
impart therapeutic effect in complicated disorders such as 
diabetes and its complications (Tiwari and Rao, 2002).  
With more than 1000 strains of Saccharomyces cerevisiae 
categorized as generally recognized as safe, yeast is 
utilized in biochemical and medical applications (Carver, 
1994) as well as many food industries such as brewing 
(Casey and Ingledew, 1983), winemaking (Shinohara et 
al., 2000) and baking (Chell, 1997). Several studies have 
demonstrated that yeast hydrolysate (YH) displays antio-
besitic (Jung et al., 2009) and antidiabetic activity (Morley
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et al., 1981; Steiner et al., 1989). For these reasons, YH 
is receiving remarkable attention as a functional sub-
stance in the diet food market. The continuing develop-
ment of functional foods is likely to entail increased use of 
different protein sources known to contain bioactive 
components. 
Cyclo-His-Pro (CHP) is a naturally occurring cyclic 
dipeptide consisting of histidyl and proline and is a meta-
bolite of thyrotropin-releasing hormone. As plasma levels 
of CHP in humans is increased after ingestion of glucose, 
CHP activity has been suggested to be related to glyce-
mic control in patients with DM. Dietary feeding of CHP 
with zinc supplementation significantly improves insulin 
sensitivity and glucose clearance in diabetic animals and 
humans (Hwang et al., 2003; Song et al., 2001; Rosenthal 
et al., 2001). Furthermore, several studies have demon-
strated that CHP decreases food intake, consequently, 
mimicking the action of leptin, the appetite control hor-
mone (Morley et al., 1981; Steiner et al., 1989). Hence, 
CHP plays an important role in regulating insulin and 
leptin sensitivity, while no evidence of toxicity or side 
effects associated with its oral administration has been 
reported (Song et al., 2005, 2009).  
We developed CHP containing high content of YH for 
possible applications of this cyclic dipeptide in metabolic 
disorder therapy. In the previous study (Jung et al., 2011), 
we increased the CHP content in the YH that was 
obtained from enzymatic hydrolysis and briefly assessed 
the antidiabetic effect by the oral glucose tolerance test 
(OGTT) in a type 1 diabetic animal model. The purpose 
of this study was to assess the anti-diabetic effect of YH 




MATERIALS AND METHODS 
 
Animals and diets 
 
The animal protocol was approved by the Korea University Animal 
Care Committee. Male Sprague-Dawley (SD) rats, obtained at 6 
weeks of age (200 ± 10 g), from Central Lab. Animal Inc. (Seoul, 
Korea) were housed individually in plastic cages with grated stain-
less steel floor. The colony was maintained at 24 ± 1°C with 60% 
relative humidity and a 12 h light/12 h dark cycle. The rats had ad 
libitum access to water and the rodent chow (Samyang Co., Seoul, 
Korea). Composition (g/100 kg of diet) of the chow was: moisture, 
80; protein, 230; fat, 35; fiber, 50; carbohydrate, 600; and water.  
 
 
Preparation of the diabetic rats  
 
STZ (Sigma-Aldrich, St. Louis, MO, USA) was used to induce 
diabetes. The animals were given intraperitoneal injections of freshly 
prepared STZ (40 mg/kg in 0.01 M citrate buffer, pH 4.5) for 5 days, 
and the normal control (NC) group was injected with 0.01 M citrate 
buffer only. Five days after STZ treatment, blood was collec-ted 
from the tip of the tail vein, and fasting glucose level was mea-
sured (Takamura et al., 1999). The STZ injection destroyed a suffi-
cient number of islet beta cells to be a model of type 1 diabetes with 
the glucose level of over 300 mg/dl. After the STZ-induction period, 
the rats were separated into four groups (six rats/group) based on 





days after the STZ injection. 
 
 
YH preparation  
 
An 8% yeast suspension was hydrolyzed for 48 h using 
Flavourzyme (endoprotease and exopeptidase from Aspergillus 
oryzae). The hydrolysis temperature was 50°C for the crude 
enzymes, and the enzyme : yeast substrate ratio was 1:100 for the 
enzymes. The hydrolysis of yeast with enzymes was performed in 
0.01 M phosphate buffer. pH was adjusted to the optimal values for 
the Flavourzyme specific proteases (pH 7.0) before hydrolysis was 
initiated. Hydrolysis was inactivated by heating at 90°C for 5 min. 
The YH obtained from enzymatic hydrolysis was first passed through 
a 0.2 μm membrane filter (Satocon cassette, Sartorius, Goettingen, 
Germany). A portion of the solution was removed immediately, and 
the filtrate was then pumped through a 10 kDa molecular weight 
cut-off membrane (Satocon cassette, Sartorius). The YH obtained 
from ultrafiltration was adsorbed with active carbon. The YH 
obtained from ultrafiltration, and the resulting substance were dried 
and used as the YH (51.0 mg/g CHP). 
 
 
YH administration  
 
YH was suspended in distilled water and administered orally 
through an intragastric tube at doses of 0.50 or 0.75 g/kg body 
weight. The volume of administrated extract was 1 ml for each ani-
mal. The rats were divided into four groups (eight rats/group): NC: 1 
ml water for normal control; DC: 1 ml water for diabetic rats; YH-1: 
0.50 g/kg body weight YH; or YH-2: 0.75g/kg body weight YH for 
diabetic rats, and each group of rats was treated daily for 14 days 
using an intragastric tube.  
At the end of the experimental period, the rats were anesthetized 
with ethyl ether, and blood was collected from the abdominal artery 
into a heparinized sterile tube. Plasma was obtained by centrifu-
gation at 1,800 × g for 30 min and stored at -80°C until further 
analysis. The liver, spleen and kidneys were excised and weighed 
after sacrificing the animals. 
 
 
Fasting blood glucose level  
 
Blood glucose levels were monitored every week after a 12 h fast in 
venous blood taken from the tail vein using a glucose analyzer. 
Fasting blood glucose was measured after 14 days of YH treatment 
during which the animals were fed a normal diet. Rats were fasted 
for 12 h, and blood was collected from the tip of the tail vein. Blood 
glucose level was measured using a blood glucose analyzer 
(Superglucocard II, Arkray Inc., Kyoto, Japan) based on the glucose 
oxidase method (Barham and Trinder, 1972). Results are 
expressed as glucose mg/dl blood. 
 
 
Oral glucose tolerance test 
 
On the day of animal sacrifice, after an overnight fast, 0 min blood 
was taken from the tip of the tail vein from all the rats. Rats that had 
been administered YH (0.75 g/kg body weight), received oral load 
of 30% glucose solution (2 g glucose/kg body weight). Blood 
samples were collected from the tail vein at 30, 60, 90 and 120 min 
after the oral glucose load and treated as described previously for 
the plasma glucose analysis (Han et al., 2007). Blood glucose level 
was expressed as increments from baseline. Incremental areas 
under the response curves (AUC) were calculated using the trape-
zoidal rule, with fasting levels considered as baseline. 
 
 
Statistical analysis  
 
All statistical analyses were performed using the Statistical Package








 Initial body weight (g) Final body weight (g) Body weight gain (g/14 days) 
Normal control 211.20 ± 1.02
2a
 236.50 ± 3.96
a
 25.30 ± 2.94
a
 
Diabetic control 195.80 ± 1.39
b
 169.30 ± 2.69
c
 -26.50 ± 1.31
d
 
Diabetic YH-1  192.10 ± 0.65
b
 179.80 ± 0.94
c
 -12.30 ± 0.29
c
 
Diabetic YH-2  195.80 ± 1.22
b
 197.00 ± 5.88
b





Diabetic YH-1; STZ-induced diabetic rats given 0.50 g/kg of yeast hydrolysate; Diabetic YH-2, STZ-induced diabetic rats given 
0.75 g/kg of yeast hydrolysate. 
2
Mean ± SEM; values with different superscripts letters within the same column are significantly 











































Figure 1. Effect of yeast hydrolysate on plasma glucose in normal and STZ-
induced diabetic rats. Values with different superscripts letters within the 
column are significantly different at P<0.05 by Duncan’s multiple range test; 
NC, 1 ml water for normal control; DC, 1 ml water for diabetic rats; YH-1, 0.50 




for Social Sciences (SPSS) version 12.0 (SPSS Inc., USA). The 
differences among groups were evaluated by one-way analysis of 
variance (ANOVA) and Duncan's multiple range tests. All data were 
reported as the mean and standard error. A level of P<0.05 was 





Body weight gain in STZ-induced mice during the 14 
day period 
 
YH or vehicle was administered orally to STZ-induced 
mice for 14 days, and body weight was measured. As 
shown in Table 1, no significant differences in initial body 
weight were observed among the STZ-diabetic groups. 
The NC group continued to gain weight until the end of 
the study. STZ produced significant body weight losses 
as compared to that in the NC group. After 14  days  of 
testing, final body weights and mean body weight gains 
were significantly lower (P<0.05) in all STZ-diabetic 
groups as compared to those of the NC group. Mean 
weight gains in the YH administered groups were signi-
ficantly higher (P<0.05) than those in the DC group, and 
significant improvements (P<0.05) in body weight were 
observed in the YH-2 group. 
 
 
Fasting blood glucose levels in STZ-induced mice 
during the 14 day period  
 
The effect of repeated oral administration of YH or vehi-
cle on fasting blood glucose levels in the STZ-diabetic 
groups during 14 days of treatment are presented in 
Figure  1.  Intraperitoneal  administration of STZ to rats








 Liver (g/100 g of body weight) Spleen (g/100 g of body weight) Kidney (g/100 g of body weight) 
Normal control 4.42 ± 0.10
2b
 0.57 ± 0.02
NS
 0.48 ± 0.04
NS
 
Diabetic control 4.92 ± 0.10
a
 0.60 ± 0.03 0.60 ± 0.06 
 Diabetic YH-1  4.52 ± 0.10
ab
 0.58 ± 0.03 0.54 ± 0.04 
Diabetic YH-2  4.42 ± 0.01
b
 0.59 ± 0.05 0.51 ± 0.05 
 
1
Diabetic YH-1, STZ-induced diabetic rats given 0.50 g/kg of yeast hydrolysate; Diabetic YH-2, STZ-induced diabetic rats given 0.75 
g/kg of yeast hydrolysate. 
2
Mean ± SEM; values with different superscripts letters within the same column are significantly different at 




caused a significant diabetogenic response with signi-
ficant increases (P<0.05) in fasting blood glucose levels 
as compared to those in the NC group. Plasma glucose 
level increased continuously in the DC group during the 
experimental period, reaching a final level of appro-
ximately 500 mg/dl. YH administered at two different 
doses of 0.50 and 0.75 g/kg body weight to the STZ-
treated diabetic groups resulted in a significant reduction 
(P<0.05) of fasting blood glucose levels, which was asso-
ciated with treatment duration. After 14 days of treatment, 
the fasting blood glucose levels in the STZ-induced dia-
betic mice treated with YH at 0.75 g/kg (193.80 ± 10.12 
mg/dl) were significantly lower (P<0.05) as com-pared to 
those of the DC group (474.00 ± 13.35 mg/dl).  
 
 
Organ weights in the STZ-induced mice 
 
We investigated the influence of YH on the liver, spleen 
and kidney weight (Table 2). The DC group (4.92 ± 0.10 
g/100 g body weight) had significantly greater (P<0.05) 
liver weights than the NC group (4.42 ± 0.10 g/100 g 
body weight). The liver weight was significantly changed 
by YH administration in a dose dependent manner. Spleen 
weight was not significantly different (P<0.05) regardless 
of diabetes induction. However, the DC group (0.60 ± 
0.03 g/100 g body weight) exhibited greater spleen weight 
than the NC (0.57 ± 0.2 g/100 g body weight) and YH 
administered groups (0.58 ± 0.03 and 0.59 ± 0.05 g/100 g 
body weight, respectively). Diabetes induced by STZ 
injection resulted in increased kidney weight; the YH 
administered groups had decreased kidney weight when 
compared with the DC group.  
 
 
Oral glucose tolerance test 
 
The OGTT and the calculated AUC were used to deter-
mine the glucose response to YH administration. As a 
result, the DC, YH-1, YH-2 and NC groups showed signi-
ficant increases (P<0.05) in blood glucose levels at 30 
min after approximately 522.00 ± 6.21, 443.00 ± 3.59, 
431.50 ± 6.29 and 209.30 ± 3.10 mg/dl glucose gavages, 
respectively. However, the DC group (248.80 ± 7.68 
mg/dl) did not recover baseline glucose level even after 
120 min. The OGTT results show that blood glucose 
decreased significantly (P<0.05) in the YH administered 
groups when compared with that in the DC group (Figure 
2A). Furthermore, the AUC was significantly smaller in 
the YH administered groups than in the DC group (Figure 
2B). The AUC of the STZ-induced diabetic mice treated 
with YH-2 was significantly smaller (P<0.05) than that in 





DM is a chronic metabolic disorder affecting a major pro-
portion of the population worldwide. Conventional thera-
pies for DM have many disadvantages such as side effects 
and a high rate of secondary failure. In contrast, natural 
sources are expected to have similar efficacy without side 
effects as those of conventional drugs. CHP exists in 
several common nutritional supplements, and it is known 
to have antiobesity effects (Jung et al., 2009) as well as 
antidiabetic activity (Morley et al., 1981; Steiner et al., 
1989). This study was undertaken to evaluate the hypo-
glycemic activity of YH with a high content of CHP in 
normal and STZ-induced diabetic rats. 
STZ is used to induce DM by selectively affecting 
pancreatic β-cells. Thus, STZ affects endogenous insulin 
release and increases blood glucose levels (So et al., 
2011). Final body weights and mean body weight gains 
were significantly lower (P<0.05) in all STZ-diabetic groups 
after 14 days of testing, as compared to those of the NC 
group (Table 1). The induction of DM with STZ is asso-
ciated with a characteristic loss of body weight due to 
increased muscle loss (Chatterjee and Shinde, 1994). 
However, hypoglycemic treatment with medicinal herbs 
may help STZ-induced diabetic rats to recover from 
hyperglycemia (Hwang et al., 2005; Prasad et al., 2009). 
Treatment with YH significantly improved body weight, 
indicating that it prevented muscle loss due to 
hyperglycemic conditions.  
The liver weights were significantly greater (P<0.05) in 
the DC group as compared to those of the NC group, and 
the YH administered groups showed significant changes 
in liver weight in a dose-dependent manner as compared 
to those of of the DC group. The lipid metabolic pathway 
is activated by acetyl-CoA in STZ-induced diabetic rats, 
rather  than  normal glucose metabolism, due to reduced














































































































































Figure 2. Effect of yeast hydrolysate on oral glucose tolerance test (A) OGTT and 
integrated area under the curves (AUCs) over a period of 0 to 120 min (B) in normal and 
STZ-induced diabetic rats). Values with different superscripts letters within the column are 
significantly different at P<0.05 by Duncan’s multiple range test. NC, 1 ml water for normal 
control; DC, 1 ml water for diabetic rats; YH-1, 0.50 g/kg body weight YH; YH-2, 0.75 g/kg 
body weight YH for diabetic rats.




insulin levels (Goldstein and Brown, 1977). Based on this 
hypothesis, increased synthesis and accumulation of 
heaptic triglycerides can be well explained by the liver 
hypertrophy in STZ-induced diabetic rats. DM induced by 
STZ resulted in increased kidney weight. The DC group 
exhibited greater kidney weight gains than the NC group. 
However, the YH administrated groups showed decreased 
kidney weights as compared to the DC group, indicating 
that renal enlargement commonly occurs in DM patients. 
The increase in kidney volume and size may be due to 
the increased glomerular filtration rate in early stage DM. 
McNeill (1999) reported that such diabetic animals deve-
lop glomerular hypertrophy, renal hyper filtration and 
enlargement, increased urinary albumin excretion, and 
glomerular extracellular matrix accumu- lation within 
weeks of DM onset. The results of this study support the 
possibility that CHP in YH might be effective in preventing 
renal failure in diabetic animals. 
The intraperitoneal administration of STZ to SD rats 
caused a significant diabetogenic response with signi- 
ficant increases in the levels of fasting blood glucose as 
compared to those of the NC group. After 14 days of 
treatment, the fasting blood glucose levels of the STZ-
induced diabetic mice treated with YH at 0.75 g/kg were 
significantly lower (P<0.05) than those of the DC group. 
As a result, in vivo treatment with YH resulted in a signi-
ficant reduction in blood glucose level due to an increased 
rate of glucose elimination. The OGTT results reveal that 
blood glucose level was significantly decreased in the YH 
administered groups as compared to that of the DC group. 
Furthermore, the AUC was significantly lower in a dose-
dependent manner (P<0.05) in the YH administered 
groups as compared to the DC group. Hyperglycemia 
was induced by intraperitoneal STZ. Maintaining blood 
glucose at levels close to normal and preventing diabetic 
complications are major goals in the treatment of DM 
(Control and Group, 1994). YH may enhance glucose uti-
lization, because it significantly decreases blood glucose 
levels in glucose-loaded rats, although the exact mec-
hanisms are unclear.  
Similar results were reported by Song et al. (2001), in 
which a prostate extract containing zinc and CHP signi-
ficantly decreased blood glucose and improved glucose 
tolerance and insulin sensitivity in STZ-induced diabetic 
rats. These results indicate that CHP has a strong ability 
to stimulate intestinal zinc absorption, cellular zinc uptake 
and promoted glucose utilization (Rosenthal et al., 2001; 
Song et al., 2001, 2003). Zinc deficiency critically affects 
DM, because zinc activates insulin receptor β-subunits, 
thereby exerting an influence on glucose metabolism 
(Song et al., 2001). Although, the exact mechanism of the 
antidiabetic effect of CHP has not been clearly esta-
blished, it is likely that CHP is involved in regulating 
insulin and leptin sensitivity by stimulating zinc metabo-
lism because of the following arguments: oral intake of 
CHP plus zinc significantly improves glucose tolerance in 





or unchanged insulin levels (Hwang et al., 2003; Song et 
al., 2001); high CHP concentrations inhibit insulin and 
glucagon secretion from islet cells in vitro (Wilber et al., 
1984); and CHP stimulates zinc transport mechanisms 
across the small intestine and muscle cell membrane to 
increase zinc use (Rosenthal et al., 2001). Accordingly, it 
is assumed that the YH-containing CHP might affect zinc 
metabolism. 
In conclusion, YH containing CHP was useful as a the-
rapeutic agent to improve glucose tolerance in diabetic 
rats. Further investigations are needed to elucidate the 
molecular mechanisms by which the antidiabetic effects 
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